Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX – Get Rating) Director Paul Black sold 60,000 shares of the firm’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $16.58, for a total transaction of $994,800.00. Following the completion of the sale, the director now owns 1,254,631 shares of the company’s stock, valued at $20,801,781.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Paul Black also recently made the following trade(s):
- On Monday, June 6th, Paul Black sold 65,450 shares of Allscripts Healthcare Solutions stock. The shares were sold at an average price of $17.30, for a total value of $1,132,285.00.
- On Friday, June 3rd, Paul Black sold 75,000 shares of Allscripts Healthcare Solutions stock. The shares were sold at an average price of $17.33, for a total value of $1,299,750.00.
- On Tuesday, May 17th, Paul Black sold 50,000 shares of Allscripts Healthcare Solutions stock. The stock was sold at an average price of $18.18, for a total value of $909,000.00.
MDRX traded down $1.15 during midday trading on Monday, hitting $15.56. 1,333,563 shares of the company traded hands, compared to its average volume of 1,845,209. The company’s 50-day moving average is $19.53 and its 200 day moving average is $19.54. The company has a quick ratio of 2.38, a current ratio of 2.38 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $1.81 billion, a PE ratio of 14.92, a price-to-earnings-growth ratio of 1.53 and a beta of 0.99. Allscripts Healthcare Solutions, Inc. has a 52 week low of $13.05 and a 52 week high of $23.25.
Allscripts Healthcare Solutions (NASDAQ:MDRX – Get Rating) last released its quarterly earnings results on Thursday, May 5th. The software maker reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.04). The firm had revenue of $142.70 million for the quarter, compared to the consensus estimate of $139.67 million. Allscripts Healthcare Solutions had a net margin of 11.60% and a return on equity of 10.97%. Allscripts Healthcare Solutions’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.13 earnings per share. On average, sell-side analysts predict that Allscripts Healthcare Solutions, Inc. will post 0.67 earnings per share for the current fiscal year.
Several institutional investors have recently modified their holdings of MDRX. JPMorgan Chase & Co. raised its stake in shares of Allscripts Healthcare Solutions by 87.7% in the fourth quarter. JPMorgan Chase & Co. now owns 7,467,089 shares of the software maker’s stock worth $137,767,000 after buying an additional 3,488,947 shares during the period. BlackRock Inc. increased its stake in shares of Allscripts Healthcare Solutions by 9.3% in the fourth quarter. BlackRock Inc. now owns 23,846,502 shares of the software maker’s stock worth $439,969,000 after purchasing an additional 2,028,119 shares in the last quarter. Invesco Ltd. raised its position in shares of Allscripts Healthcare Solutions by 86.6% during the 4th quarter. Invesco Ltd. now owns 2,227,469 shares of the software maker’s stock valued at $41,097,000 after purchasing an additional 1,033,924 shares during the period. Norges Bank purchased a new position in shares of Allscripts Healthcare Solutions during the 4th quarter valued at $16,809,000. Finally, Vanguard Group Inc. boosted its holdings in Allscripts Healthcare Solutions by 4.4% in the 1st quarter. Vanguard Group Inc. now owns 13,852,474 shares of the software maker’s stock worth $311,957,000 after buying an additional 584,339 shares during the period.
A number of research firms have recently weighed in on MDRX. Piper Sandler reduced their target price on shares of Allscripts Healthcare Solutions from $19.00 to $17.00 in a research report on Thursday. Deutsche Bank Aktiengesellschaft upgraded shares of Allscripts Healthcare Solutions from a “hold” rating to a “buy” rating and lifted their target price for the company from $20.00 to $26.00 in a report on Friday, March 4th. SVB Leerink upped their price target on Allscripts Healthcare Solutions from $22.00 to $24.00 and gave the stock an “outperform” rating in a research note on Thursday, March 3rd. TheStreet cut Allscripts Healthcare Solutions from a “b” rating to a “c” rating in a research note on Friday, May 6th. Finally, StockNews.com cut shares of Allscripts Healthcare Solutions from a “buy” rating to a “hold” rating in a research note on Friday, May 13th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Allscripts Healthcare Solutions has an average rating of “Buy” and a consensus price target of $21.40.
Allscripts Healthcare Solutions Company Profile (Get Rating)
Allscripts Healthcare Solutions, Inc, together with its subsidiaries, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions.
Further Reading
Receive News & Ratings for Allscripts Healthcare Solutions Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Allscripts Healthcare Solutions and related companies with MarketBeat.com’s FREE daily email newsletter.
link